Reuters reported on Sept 18 2026 that Anthropic has set up a wet lab in the San Francisco Bay Area, sourcing the existence of the facility to "two people familiar with the matter." Critically, the story is not left at rumor level: Anthropic's head of life sciences, Eric Kauderer-Abrams, confirmed the lab on the record in a Reuters interview. The quotations reproduced in the Instagram caption match the wire copy, including "We absolutely are doing that today," and his description of the setup as typical of biotech companies, with some work in-house and some with external partners.

An Anthropic spokesperson then added a limiting statement to Reuters: the lab is "not for drug discovery specifically," and declined to elaborate. TechCrunch obtained its own confirmation the same day and reported that Anthropic said the main focus is fundamental biology rather than drug discovery, noting the company does not want to appear to compete with pharma customers and partners. Multiple outlets record that Anthropic would not disclose the lab's size, staff count, opening date, or biosafety level.

Surrounding context is well documented: Anthropic launched its Life Sciences Verification Program on Sept 17 2026 through its own newsroom, acquired biotech AI startup Coefficient Bio in a reported roughly $400 million stock deal in April 2026, and has publicly stated ambitions around rare-disease treatments. Anthropic's own job listings describe a Life Sciences team doing hands-on biological research including wet-lab components.